Insulin potentiates platelet-derived growth factor action in vascular smooth muscle cells

Endocrinology

Volumn 139, Issue 10, 1998, Pages 4067-4072

  Goalstone, Marc L ^c   Natarajan, Rama ^a   Standley, Paul R ^b   Walsh, Mary F ^b   Leitner, J Wayne ^c   Carel, Kirsten ^c   Scott, Steven ^a   Nadler, Jerry ^a   Sowers, James R ^b   Draznin, Boris ^c  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROINSULIN; PROTEIN FARNESYLTRANSFERASE INHIBITOR; VASCULOTROPIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY WALL; ARTICLE; ATHEROSCLEROSIS; CELL GROWTH; CEREBROVASCULAR DISEASE; CORONARY ARTERY DISEASE; CROSS REACTION; ENZYME ACTIVITY; ENZYME INHIBITION; HYPERINSULINEMIA; HYPOTHESIS; INSULIN METABOLISM; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; NONHUMAN; PATHOGENESIS; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RAT; RISK FACTOR; STROKE; VASCULAR SMOOTH MUSCLE;

EID: 14444278515     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.139.10.6270     Document Type: Article

References (52)

1. Stout RW, Vallance-Owen J 1969 Insulin and atheroma. Lancet 1:1078-1080
2. Stout RW 1996 Hyperinsulinemia and atherosclerosis. Diabetes 45:45-46
3. Pyorala K 1979 Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: Results from two populations in Finland. Diabetes Care 2:131-141
4. Welborn TA, Wearne K 1979 Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care 2:154-160
5. Fontbonne A, Charles MS, Thibult N, Richard JL, Claude JR, Warnet JM, Rosselin GE, Eschwege E 1991 Hyperinsulinemia as a predictor of coronary heart disease mortality in a healthy population: The Paris Prospective Study, 15-year follow-up. Diabetologia 34:356-361
6. Després J-P, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, Lupien PJ 1996 Hyperinsulinemia as an independent risk factor of ischemic heart disease. N Engl J Med 334:952-957
7. Welin L, Eriksson H, Larsson B, Ohlson LO, Svärdsudd K, Tibblin G 1992 Hyperinsulinemia is not a major coronary risk factor in elderly men: the study of men born in 1913. Diabetologia 35:766-770
8. Hargreaves AD, Logan RL, Elton RA, Buchanan KD, Oliver MF, Riemersmaa RA 1992 Glucose intolerance, plasma insulin, HDL cholesterol and obesity: 12-year follow-up and development of coronary heart disease in Edinburgh men. Atherosclerosis 94:61-69
9. Ferrara LA, Mancini M, Celentano A, Galderisi M, lannuzzi R, Marotta T, Gaeta I 1994 Early changes of the arterial carotid wall in uncomplicated primary hypertensive patients. Arterioscler Thromb 14:1290-1296
10. Folsom AR, Eckefeldt JH, Weitzman S, Chambless LE, Barnes RW, Cram KB, Hutchinson RG 1994 Atherosclerosis Risk in Communities (ARIC) Study investigators: relation of carotid artery wall thickness to diabetes mellitus, fasting glucose and insulin, body size, and physical activity. Stroke 25:66-73
11. Salomaa V, Riley W, Kark JK, Nardo C, Folsom AR 1995 Non-insulin dependent diabetes mellitus and fasting glucose and insulin concentrations are associated with arterial stiffness indexes: the ARIC study. Circulation 91:1432-1443
12. Agewall S, Fageberg B, Attvall S, Wendelhag I, Urbanavicius V, Wikstrand J 1995 Carotid artery wall intima-media thickness is associated with insulin-mediated glucose disposal in men at high and low coronary risk. 1995. Stroke 26:956-960
13. Shinozaki K, Naritomi H, Shimizu T, Suzuki M, Ikebuchi M, Sawada T, Harano Y 1996 Role of insulin resistance associated with compensatory hyperinsulinemia in ischemic stroke. Stroke 27:37-43
14. Shinozaki K, Suzuki M, Ikebuchi M, Takaki H, Hara Y, Tsushima M, Harano Y 1995 Insulin resistance associated with compensatory hyperinsulinemia as an independent risk factor for vasospastic angina. Circulation 92:1749-1757
15. Laakso M, Lehto S, Penttila I, Pyorala K 1993 Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin dependent diabetes.Circulation 88:1421-1430
16. Kannel WB, McGee DL 1979 Diabetes and cardiovascular risk factors: The Framingham Study. Circulation 1:8-13
17. Pan WH, Cedres LB, Liu K, Dyer A, Schoenberger JA, Shekelle RB, Stamler R, Smith D, Collette F, Stamler J 1986 Relationship of clinical diabetes and asymptomatic hyperglycemia to risk of coronary heart disease mortality in men and women. Am J Epidemiol 123:504-516
18. Stamler J, Vaccaro O, Neaton JD, Wentworth D, for the Multiple Risk Factor Intervention Trial Group 1993 Diabetes, other risk factors and 12-year cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 16:434-444
19. Janka HU, Ziegler AG, Standl E, Mehnert H 1987 Daily insulin dose as a predictor of macrovascular disease in insulin-treated non-insulin dependent diabetics. Diabetes Metab 13:359-364
20. Stolar MW 1988 Atherosclerosis in diabetes: the role of hyperinsulinemia. Metab Clin Exp [Suppl 1] 2:1-9
21. Knight TM, Smith Z, Whittles A, Sahota F, Lockton JA, Hogg G, Bedford A, Toop M, Kernohan EEM, Baker MR 1992 Insulin resistance, diabetes, and risk markers for ischemic heart disease in Asian men and non-Asian men in Bradford. Br Heart J 67:343-350
22. Ronnemaa T, Laakson M, Pyorala K, Kallio V, Puukka P 1991 High fasting plasma insulin is an indicator of coronary heart disease in non-insulin dependent diabetic patients and non-diabetic subjects. Arterioscler Thromb 11:80-90
23. Uusitupa MIJ, Niskanen LK, Siitonen O, Voutilainen E, Pyorala K 1990 5-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin dependent diabetic and non-diabetic subjects. Circulation 82:27-36
24. Reaven GM 1988 Role of insulin resistance in human disease. Diabetes 37:1595-1607
25. DeFronzo RA, Ferrannini E 1991 Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14:173-194
26. Sowers JR, Sowers PS, Peuler JD 1994 Role of insulin resistance and hyperinsulinemia in development of hypertension and atherosclerosis. J Lab Clin Med 123:647-652
27. Goalstone ML, Draznin B 1996 Effect of insulin on farnesyltranserase activity in 3T3-L1 adipocytes. J Biol Chem 271:27585-27589
28. Leitner JW, Kline T, Carel K, Goalstone M, Draznin B1997 Hyperinsulinemia potentiates activation of p21Ras by growth factors. Endocrinol 138:2211-2214
29. Goalstone M, Carel K, Leitner JW, Draznin B 1997 Insulin stimulates the phosphorylation and activity of farnesyltransferase via the Ras-MAP kinase pathway. Endocrinology 138:5119-5124
30. Zhang FL, Casey RJ 1996 Protein prenylation: molecular mechanisms and functional consequences. Ann Rev Biochem 65:241-269
31. Kikuchi A, Williams LT 1994 The post-translational modification of Ras p21 is important for Raf-1 function. J Biol Chem 269:20054-20059
32. Dominguez LJ, Davidoff AJ, SrinivasPR, Standley PR, Walsh MF, Sowers JR 1996 Effects of metformin on tyrosine kinase activity, glucose transport, and intracellular calcium in rat vascular smooth muscle. Endocrinology 137:113-121
33. Natarajan R, Gu JL, Rossi J, Gonzales N, Lanting L, Xu L, Nadler JL 1993 Elevated glucose and angiotensin II increase 12-lipoxygenase activity and expression in porcine aortic smooth muscle cells. Proc Natl Acad Sci USA 90:4947-4951
34. Burgering BMT, Boss J 1995 Regulation of Ras-mediated signaling: more than one way to skin a cat. Trends Biochem Sci 20:18-22
35. Stavri GT, Hong Y, Zachary IC, Breier G, Baskerville PA, Yia-Herttuala S, Risau W, Martin JF, Erusalimsky JD 1995 Hypoxia and platelet-derived growth factor-BB synergistically upregulate the express of vascular endotheial growth factor in vascular smooth muscle cells. FEBS Lett 358:311-315
36. Williams B, Quinn-Baker A, Gallacher B 1995 Serum and platelet-derived growth factor-induced expression of vascular permeability factor mRNA by human vascular smooth muscle cells in vitro. Clin Sci 88:141-147
37. Macara IG, Lounsburg KM, Richards SA, McKierman C, Bar-Sagi D 1996 The Ras superfamily of GTPases. FASEB J 10:625-630
38. Lander HM, Tauras JM, Ogiste JS, Hori O, Moss RA, Schmidt AM 1997 Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 272:17810-17814
39. King GL, Goodman AD, Buzney S, Moses A 1985 Receptors and insulin-like growth factors on cells from bovine retinal capillaries and aorta. J Clin Invest 75:1028-1036
40. Barkis GL, Plant CE, Walsh MF, Sowers JR 1996 Analogy between endothelial/mesangial cell and endothelial/vascular smooth muscle cell interactions: role of growth factors and mechanotransduction. In: Sowers JR (ed), Totowa NJ, Endocrinology of the vasculature. Humana Press, pp 341-355
41. Sowers JR 1997 Insulin and insulin-like growth factor in normal and pathological cardiovascular physiology. Hypertension 29:691-699
42. Inaba T, Ishibashi S, Gotoda T, Kawamura M, Morino N, Nojima Y, Kawakami M, Yazaki Y, Yamada N 1996 Enhanced expression of platelet-derived growth factor-beta receptor by high glucose: involvement of platelet-derived growth factor in diabetes angiopathy. Diabetes 45:507-512
43. Williams LT 1989 Signal transduction by the platelet-derived growth factor receptor. Science 243:1564-1570
44. Jawien A., Bowen-Pope DF, Lindner V, Schwartz SM, Clowes AW 1993 Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J Clin Invest 89:507-511
45. Ross R, Raines WE, Bowen-Pope DF 1986 The biology of platelet-derived growth factor. Cell 46:155-169
46. Leung DW, Cachianes G, Knang WJ, Goeddel DW, Ferrara N 1989 Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:1306-1309
47. Clauss MM, Gerlach H, Brett J, Wang F, Familletti PC, Pan YCE, Olander JV, Connolly DT, Stern D 1990 Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Ext Med 172:1535-1545
48. Connolly DT, Heuvelman DM, Nelson R, Olander JV, Eppley BL, Delfino JJ, Siegel NR, Leimbruber RM, Feder J 1989 Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 84:1470-1478
49. Ross R 1993 The pathogenesis of arherosclerosis: a perspective for the 1990s. Nature 362:801-809
50. Williams B, Baker AQ, Gallacher B, Lodwick D 1995 Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells. Hypertension 25:913-917
51. Kuzuya M, Satake S, Esaki T, Yamada K, Hayashi T, Naito M, Asai K, Iguchi A 1995 Induction of angiogenesis by smooth muscle cell-derived factor: possible role in neovascularization in atherosclerotic plaque. J Cell Physiol 164:658-667
52. Gibbs JB, Pompliano DL, Mosser SD, Rands E, Lingham RB, Singh SB, Scolnick EM, Kohl N, Oliff A 1993 Selective inhibition of farnesyl-protein transferase blocks ras processing in vivo. J Biol Chem 268:7617-7620